Peptilogics is a surgical therapeutics company dedicated to curing and preventing medical device-related infections (MDRI). The company's lead candidate, PLG0206, is a first-in-class drug designed to target biofilm, a protective bacterial matrix that is the root cause of device infections across multiple surgical categories. PLG0206 is currently being evaluated in a Phase 2/3 registration trial for the treatment of prosthetic joint infection (PJI), representing the first of multiple potential indications. The company employs scalable, rational design approaches to develop treatments for infections that currently have no approved cures.
Beta · Sourced from candidate reports
Be the first to share your experience with Peptilogics.
Your reply helps other candidates know what to expect.
